In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2197-2203

  Mougenot, Philippe ^a,b   Bressolle, Françoise ^a,b   Culine, Stéphane ^a   Solassol, Isabelle ^a   Poujol, Sylvain ^a   Pinguet, Fréderic ^a  

^a CENTRE VAL D AURELLE   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

24 hour continuous infusion; Hormone refractory prostate cancer; Melphalan; PC 3 cell line; Survival

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANDROGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; HORMONE; MELPHALAN; MITOXANTRONE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CELL CULTURE; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELPHALAN; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PILOT PROJECTS; PROSTATIC NEOPLASMS;

EID: 33745561802     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Culine S and Droz JP: Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Ann Oncol 11: 1523-1530, 2000.
2. Robson M and Dawson N: How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 10: 727-747, 1996.
3. Goktas S and Crawford ED: Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 26: 162-173, 1999.
4. Carter SK and Wasserman TH: The chemotherapy of urologic cancer. Cancer 36: 729-747, 1975.
5. Catane R, Kaufman JH, Madajewicz S, Mittelman A and Murphy GP: Prednimustine therapy for advanced prostatic cancer. Br J Urol 50: 29-32, 1978.
6. Veronesi A, Zattoni F, Frustaci S, Galligioni E, Tirelli U, Trovo G, Tumolo S, Merlo A, Artuso G, Cosciani-Cunico S and Grigoletto E: Estramustine phosphate (Estracyt) treatment of T3-T4 prostatic carcinoma. Prostate 3: 159-164, 1982.
7. Nichols WC, Kvols LK, Richardson RL and Benson RC: A phase II study of azyridinybenzoquinone (AZQ) in advanced genitourinary cancer. Proc Am Soc Clin Oncol 1: 117-119, 1982.
8. Smith DC, Jodrell DI, Egorin MJ, Ambinder RM, Zuhowski EG, Kreis W, Ellis PG and Trump DL: Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. Cancer Chemother Pharmacol 31: 363-368, 1993.
9. Beer TM, Pierce WC, Lowe BA and Henner WD: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12: 1273-1279, 2001.
10. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000.
11. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM and Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996.
12. Teicher BA, Kakeji Y, Ara G, Herbst RS and Northey D: Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo 11: 453-461, 1997.
13. Samuels B and Bitran JD: High-dose intravenous melphalan: a review. J Clin Oncol 13: 1786-1799, 1995.
14. Vogelzang NJ: Continuous infusion chemotherapy: a critical review. J Clin Oncol 2: 1289-1299, 1984.
15. Tattersall MH, Jarman M, Newlands ES, Holyhead L, Milstead RA and Weinberg A: Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 14: 507-513, 1978.
16. Pinguet F, Martel P, Rouanet P, Fabbro M and Astre C: Effect of sodium chloride concentration and temperature on melphalan stability during storage and use. Am J Hosp Pharm 57: 2701-2702, 1994.
17. Pinguet F, Bressolle F, Culine S, Fabbro M, Astre C and Chevillard C: Influence of the schedule of exposure on the cytotoxic effect of melphalan toward human 8226 and A2780 cells. Eur J Cancer 55: 1402-1406, 1999.
18. Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C and Fabbro M: A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Clin Cancer Res 6: 57-63, 2000.
19. Olive PL, Wlodek D and Banath JP: DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. Cancer Res 51: 4671-4676, 1991.
20. Skehan P, Storeng R and Scuderio G: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
21. Cockcroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31, 1976.
22. Mougenot P, Pinguet F, Fabbro M, Culine S, Poujol S, Astre C and Bressolle F: Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol 55: 503-512, 2004.
23. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL and Wilding G: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467, 1999.
24. Erratum in: J Clin Oncol 18: 2644, 2000.
25. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 50: 7-33, 2000.
26. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP and Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506-2513, 1999.
27. Beer TM, Pierce WC, Lowe BA and Henner WD: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12: 1273-1279, 2001.
28. Berry W, Dakhil S, Gregurich MA and Asmar L: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28(4 Suppl 15): 8-15, 2001.
29. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ and Logothetis C: Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22: 3323-3329, 2004.
30. Lokich JJ: Alkylating agents with infusional schedules of delivery. J Infusion Chemother 1: 17-23, 1991.
31. Woodhouse KW, Hamilton P, Lennard A and Rawlins MD: The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Eur J Clin Pharmacol 24: 283-285, 1983.
32. Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM and Ozols RF: Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 44: 5427-5431, 1984.
33. Bosanquet AG and Gilby ED: Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18: 355-362, 1982.
34. Sarosy G, Leyland-Jones B, Soochan P and Cheson BD: The systemic administration of intravenous melphalan. J Clin Oncol 11: 1768-1782, 1988.